Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial

NCT07073469 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

330

Enrollment

OTHER

Sponsor class

Conditions

Stroke Ischemic

Interventions

DRUG: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
OTHER: Standard medical treatment

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University